Developer docs
API playgroundTry for free, no card

Search company profiles

BioNews

Full company profile

uuid002xvyw

Namestring
BioNews
Legal namestring
Bionews Inc.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

BioNews Inc., founded in 2013 and headquartered at 3 W Garden St, Suite 700, Pensacola, Florida, operates a network of 50+ rare and chronic disease patient community websites that aggregate news, forums, video content, and patient-reported data on conditions including ALS, Friedreich's ataxia, SMA, Myasthenia Gravis, Alzheimer's, and Pompe disease. The platform reaches 1.5M+ monthly engaged patients with a 95% diagnosis-confirmed audience and reports 3-5x industry-average engagement rates and a 7-minute average session duration. The platform's underlying technology stack combines disease-specific community sites with proprietary research assets including RareSignal Intelligence (a patient intelligence product drawing on behavioral data from the 50+ communities), the Rare Trust in AI Index (a quarterly research product tracking patient trust in AI-generated health information), and a recurring nationwide rare disease survey (the 2024 wave reached 5,032 respondents). More than 50% of Bionews employees are living with or caring for someone with a rare condition, which is positioned as a content and community authenticity differentiator.

BioNews generates revenue through four enterprise B2B streams sold to pharmaceutical companies, biotechs, clinical research organizations (CROs), and patient advocacy organizations. Media & Advertising integrates brands into the trusted community environments via eNewsletters, sponsored content, brand pages, and video. Clinical Trial Recruitment Services accelerate rare disease trial enrollment by referring patients matching diagnosis, history, and location, with revenue recognized via referral or service fees. Market Research & Insights (RareSignal) monetizes custom studies, rapid polls, and focus groups as a research service. Advocacy Partnerships & Sponsored Content produces patient storytelling and awareness campaigns. Pricing is bespoke and partnership-based with multi-year contracts; there are no publicly listed tiers or consumer-facing products. Commercial customers named in source material include the top 20 pharmaceutical companies, with specific testimonial evidence from Publicis Health Media, CMI Media Group, Heartbeat Ideas, and Blue Owl Agency (healthcare media agencies) and a Top 10 Pharma VP of Patient Engagement.

The go-to-market motion is direct enterprise field sales with a strategic partnerships team responding to inbound inquiries within one business day, supplemented by presence at the annual World Orphan Drug Congress and hosted webinars including the RWE Series. Distribution is exclusively B2B; the 1.5M+ patient audience is leveraged as the underlying asset driving client value rather than monetized directly to consumers. Distribution is also anchored in the company's owned-media footprint: SEO-optimized disease-specific news sites, owned newsletters, organic social (Facebook, LinkedIn, Instagram), and earned media coverage of proprietary research. Operational footprint is concentrated at the Pensacola headquarters, but the company claims a global audience and serves pharmaceutical clients internationally.

Short descriptiontext

BioNews operates a network of 50+ rare disease patient community websites reaching 1.5M+ monthly diagnosis-confirmed patients, selling pharmaceutical companies enterprise media advertising, RareSignal market research, clinical trial recruitment, and advocacy partnership services through a direct strategic partnerships sales motion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPensacola, United States
HQ citystring
Pensacola
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease media, patient community platform, clinical trial recruitment, pharma advertising solutions, patient market research
Industry3 codes
PRIMARYMPACAJAL
Health, Wellness & Patient Communities
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Media Streaming Distribution Services, Social Networks, and Other Media Networks and Content Providers51621
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Newspaper, Periodical, Book, and Directory Publishers5131
SIC code2 codes
  • Services-Health Services8000
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Patient Media & Insights
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Media & Advertising
TypeAdvertising
Description

Pharma and healthcare brands pay to integrate within Bionews' trusted rare disease communities through targeted solutions including eNewsletters/eBlasts, targeted media, sponsored content hubs, brand pages, video advertising, DSE sponsorship, and awareness month campaigns.

bionews.com
2Clinical Trial Recruitment Services
TypeProfessional Services
Description

Bionews accelerates rare disease clinical trial recruitment by reaching engaged, condition-specific patient communities, educating patients and connecting them with trials matching their diagnosis, treatment history, and location — generating referral fees from pharma/biotech clients.

bionews.com
3Market Research & Insights (RareSignal)
TypeData Monetisation
Description

Custom studies, rapid polls, pulse surveys, focus groups, and market research surveys offered to pharma and biotech partners seeking condition-specific patient intelligence, billed as a research service.

bionews.com
4Advocacy Partnerships & Sponsored Content
TypeProfessional Services
Description

Sponsored storytelling, patient collaborations, and awareness initiatives with patient advocacy organizations and pharma partners. Includes editorial and content partnerships and HCP engagement programs.

bionews.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise / partnership-based pricing — no public tier list
ModelOtherBilling cadenceMulti-year contract
Notes

All solutions are quoted on a bespoke basis through the partnerships team. No standard pricing tiers are published on the website.

bionews.com
GTM typeB2B
B2B
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

BioNews operates a digital health media platform that aggregates 50+ rare and chronic disease patient communities into a single network offering news, forums, video content, and patient-reported data. It monetizes this audience by selling targeted Media & Advertising, RareSignal Research & Insights, Clinical Trial Recruitment, and Advocacy Partnerships solutions to pharmaceutical companies, biotechs, CROs, and patient advocacy organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 3–5x industry-average engagement rate
+5 more records
Product overview1 text field

BioNews operates as a unified platform consisting of a core network of 50+ rare and chronic disease community websites, supported by integrated service modules for Media & Advertising (targeted brand integration), RareSignal Research & Insights (patient survey and market research capabilities), Clinical Trial Support (patient recruitment), and Advocacy Partnerships. The company also produces branded content products including The Rare Journey immersive storytelling series and the Rare Trust in AI Index research publication. The platform serves both rare disease patients seeking information and pharmaceutical/clinical partners seeking to reach engaged, diagnosis-confirmed patient audiences.

Product and service7 records
1Rare Disease News & Community Network
CategoryPatient Community Media
Description

Network of 50+ rare and chronic disease news and community websites offering breaking research news, patient stories, forums, resource pages, advocacy partnerships, and social connections across conditions including ALS, Alzheimer's, Pompe, SMA, Myasthenia Gravis, and 45+ others. Built for rare disease patients, caregivers, and the pharma/biotech clients seeking to reach diagnosis-confirmed audiences.

2Media & Advertising
CategoryMedia & Advertising Solutions
Description

Targeted media solutions integrating brands within BioNews' trusted rare disease communities through eNewsletters, sponsored content hubs, brand pages, webinars, video content, conference coverage, and patient storytelling, reaching patients in clinical mindset moments. Sold to pharmaceutical and healthcare brand clients.

3RareSignal (Research & Insights)
CategoryMarket Research & Insights
Description

Custom studies, rapid polls, panel development, focus groups, market research surveys, recruitment support, brand perception analysis, competitive analysis, patient input on trial design, and quality of life impact research delivered through BioNews' 50+ rare disease communities. Sold to pharma and biotech partners as a research service.

4Clinical Trial Support
CategoryClinical Trial Recruitment Services
Description

Rare disease clinical trial recruitment through education, awareness building, and study design input. Connects patients with trials matching diagnosis, treatment history, and location for faster enrollment and higher retention. Sold to pharma, biotech, and CRO clients.

5Advocacy Partnerships
CategoryAdvocacy & Sponsored Content
Description

Collaborative programs with patient advocacy organizations to amplify advocacy efforts, expand access to reliable information, and support a more confident and engaged rare disease journey. Includes sponsored storytelling, patient collaborations, awareness initiatives, editorial and content partnerships, and HCP engagement programs.

6The Rare Journey
CategoryImmersive Patient Storytelling
Description

Immersive multimedia storytelling experience showcasing personal patient journey narratives, featuring Matt Lafleur's Friedreich's ataxia journey. Provides support and peer-to-peer connections for rare disease communities.

7Rare Trust in AI Index
CategoryResearch Index / Data Product
Description

Proprietary quarterly research index tracking how rare disease patients evaluate AI-generated health information against human-authored sources, providing insights on patient AI adoption and trust patterns across BioNews communities.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

DiMe (Digital Medicine Society) CEO Jennifer Goldsack participated as a panelist in the Bionews RWE Series webinar 'The Future of RWE' on June 23, 2026, discussing real-world evidence trends.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Megan Freed, Senior Director of Data & Health Technology Integration at Parent Project Muscular Dystrophy, participated as a panelist in the Bionews RWE Series webinar 'The Future of RWE'.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Tré LaRosa, Associate Project Manager at the Foundation for the National Institutes of Health, participated as a panelist in the Bionews RWE Series webinar.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Rachel Smith, Vice President of Rare and Genetic Disease at Parexel, participated as a panelist in the Bionews RWE Series webinar.

5Decentralized Trials & Research Alliance (DTRA)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Craig Lipset, Co-founder of DTRA, participated as a panelist in the Bionews RWE Series webinar discussing real-world evidence and decentralized trials.

bionews.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Moshe Vardi, MD, Vice President of R&D and Global Head of Clinical Development at CSL Behring, participated as a panelist in the Bionews RWE Series webinar.

7Journal of Participatory Medicine
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Amy Price, MS, MA, MS, DPhil, Editor in Chief of the Journal of Participatory Medicine, participated as a panelist in the Bionews RWE Series webinar 'The RWE Blindspot'.

bionews.com
8Rona's Fun Lab
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Lindsey Wahlstrom, Co-founder & Chief Momatologist at Rona's Fun Lab, participated as a panelist in the Bionews RWE Series webinar 'The RWE Blindspot'.

bionews.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-29
Description

The Mayo Clinic PaSAGE (Patient-powered research for Advancement of Gene therapy Evidence) Study Team collaborates with Bionews to advance rare disease awareness and integrate patient voices into the therapeutic research process. PaSAGE is funded by the NIH. Bionews serves as a virtual forum where researchers, policymakers, and patients exchange ideas on gene editing. Marcella Debidda, President of Bionews Patient Insights & Clinical Solutions, participates in NIH-funded deliberative events alongside ethicists, gene therapists, philosophers, policymakers, and genetic counselors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bionews partners with patient advocacy organizations across its 50+ communities to amplify advocacy efforts, expand access to reliable information, and support patient journeys. Bionews provides platforms for advocacy groups to reach patients and contribute resources, forums, and support to communities.

11Top 20 Pharmaceutical Companies (Client Partners)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Bionews counts the top 20 pharmaceutical companies among its client base, providing media, research, and clinical trial recruitment solutions. These partnerships are commercial client relationships where pharma companies pay for access to Bionews' patient communities.

bionews.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical trial access platform focused on improving patient recruitment and trial awareness. Comparable enterprise motion to pharma and CROs though with less emphasis on condition-specific community depth.

TypeDirect peer
Description

Long-standing patient recruitment and engagement agency for clinical trials across therapeutic areas. Comparable enterprise sales motion to pharma and CROs for trial enrollment acceleration.

TypeBroad incumbent
Description

Large general-consumer health media property owned by RVO Health, monetized via pharma advertising and content partnerships. Competes for the same pharma media budgets but without BioNews' diagnosis-confirmed, rare-disease depth.

TypeDirect peer
Description

Patient influencer network connecting pharma and biotech with patient leaders across chronic and rare conditions. Closely comparable to BioNews' patient-community and lived-experience model for pharma engagement and insights.

TypeDirect peer
Description

Specializes in connecting rare disease patients and caregivers to market research and clinical trial opportunities. Directly competes with BioNews' RareSignal research and clinical trial recruitment offerings in the rare disease vertical.

TypeOthers
Description

Rare disease policy and advocacy organization that convenes patient communities and engages with pharma/biotech. Adjacent ecosystem participant rather than a commercial competitor, but overlaps on patient-voice and pharma partnerships.

TypeDirect peer
Description

Clinical trial matching platform that recruits patients from partner communities for sponsors and CROs. Comparable to BioNews' clinical trial recruitment revenue stream and pharma partner motion.

TypeDirect peer
Description

Operates condition-specific patient communities and partners with life sciences companies for research, clinical trial recruitment, and real-world evidence. Directly comparable as a community-platform-to-pharma intermediary.

9SmartPatients
TypeEmerging player
Description

Online patient community with an embedded clinical trial matching tool and pharma insights offerings. Niche overlap with BioNews on community-driven trial recruitment and patient intelligence.

10WebMD
TypeBroad incumbent
Description

Broad health information platform with significant pharma media and sponsored content revenue. A large incumbent that competes for pharma media dollars but lacks BioNews' rare disease community authenticity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioNews

Rare Disease Patient Media & Insightsmitochondrialdiseasenews.com

BioNews operates a network of 50+ rare disease patient community websites reaching 1.5M+ monthly diagnosis-confirmed patients, selling pharmaceutical companies enterprise media advertising, RareSignal market research, clinical trial recruitment, and advocacy partnership services through a direct strategic partnerships sales motion.

What BioNews does

BioNews Inc., founded in 2013 and headquartered at 3 W Garden St, Suite 700, Pensacola, Florida, operates a network of 50+ rare and chronic disease patient community websites that aggregate news, forums, video content, and patient-reported data on conditions including ALS, Friedreich's ataxia, SMA, Myasthenia Gravis, Alzheimer's, and Pompe disease. The platform reaches 1.5M+ monthly engaged patients with a 95% diagnosis-confirmed audience and reports 3-5x industry-average engagement rates and a 7-minute average session duration. The platform's underlying technology stack combines disease-specific community sites with proprietary research assets including RareSignal Intelligence (a patient intelligence product drawing on behavioral data from the 50+ communities), the Rare Trust in AI Index (a quarterly research product tracking patient trust in AI-generated health information), and a recurring nationwide rare disease survey (the 2024 wave reached 5,032 respondents). More than 50% of Bionews employees are living with or caring for someone with a rare condition, which is positioned as a content and community authenticity differentiator.

BioNews generates revenue through four enterprise B2B streams sold to pharmaceutical companies, biotechs, clinical research organizations (CROs), and patient advocacy organizations. Media & Advertising integrates brands into the trusted community environments via eNewsletters, sponsored content, brand pages, and video. Clinical Trial Recruitment Services accelerate rare disease trial enrollment by referring patients matching diagnosis, history, and location, with revenue recognized via referral or service fees. Market Research & Insights (RareSignal) monetizes custom studies, rapid polls, and focus groups as a research service. Advocacy Partnerships & Sponsored Content produces patient storytelling and awareness campaigns. Pricing is bespoke and partnership-based with multi-year contracts; there are no publicly listed tiers or consumer-facing products. Commercial customers named in source material include the top 20 pharmaceutical companies, with specific testimonial evidence from Publicis Health Media, CMI Media Group, Heartbeat Ideas, and Blue Owl Agency (healthcare media agencies) and a Top 10 Pharma VP of Patient Engagement.

The go-to-market motion is direct enterprise field sales with a strategic partnerships team responding to inbound inquiries within one business day, supplemented by presence at the annual World Orphan Drug Congress and hosted webinars including the RWE Series. Distribution is exclusively B2B; the 1.5M+ patient audience is leveraged as the underlying asset driving client value rather than monetized directly to consumers. Distribution is also anchored in the company's owned-media footprint: SEO-optimized disease-specific news sites, owned newsletters, organic social (Facebook, LinkedIn, Instagram), and earned media coverage of proprietary research. Operational footprint is concentrated at the Pensacola headquarters, but the company claims a global audience and serves pharmaceutical clients internationally.

BioNews firmographics

Firmographics
Name
BioNews
Legal name
Bionews Inc.
Website
https://mitochondrialdiseasenews.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
BioNews operates a network of 50+ rare disease patient community websites reaching 1.5M+ monthly diagnosis-confirmed patients, selling pharmaceutical companies enterprise media advertising, RareSignal market research, clinical trial recruitment, and advocacy partnership services through a direct strategic partnerships sales motion.
Ownership category
akta.pro rank

BioNews industry classification

Industry
Product category
Rare Disease Patient Media & Insights
NAICS
Media Streaming Distribution Services, Social Networks, and Other Media Networks and Content Providers (51621), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Newspaper, Periodical, Book, and Directory Publishers (5131)
SIC
Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYMPACAJAL
Health, Wellness & Patient Communities
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Rare disease media
  • Patient community platform
  • Clinical trial recruitment
  • Pharma advertising solutions
  • Patient market research

Where BioNews is headquartered

Location

Headquarters

HQ city
Pensacola
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioNews business model

Business model
GTM type
B2B
Offering type
Digital Commerce or Content
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Media & Advertising: Pharma and healthcare brands pay to integrate within Bionews' trusted rare disease communities through targeted solutions including eNewsletters/eBlasts, targeted media, sponsored content hubs, brand pages, video advertising, DSE sponsorship, and awareness month campaigns.
  2. Clinical Trial Recruitment Services: Bionews accelerates rare disease clinical trial recruitment by reaching engaged, condition-specific patient communities, educating patients and connecting them with trials matching their diagnosis, treatment history, and location — generating referral fees from pharma/biotech clients.
  3. Market Research & Insights (RareSignal): Custom studies, rapid polls, pulse surveys, focus groups, and market research surveys offered to pharma and biotech partners seeking condition-specific patient intelligence, billed as a research service.
  4. Advocacy Partnerships & Sponsored Content: Sponsored storytelling, patient collaborations, and awareness initiatives with patient advocacy organizations and pharma partners. Includes editorial and content partnerships and HCP engagement programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise / partnership-based pricing — no public tier list

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

BioNews product offering

Product offering

Core offering

BioNews operates a digital health media platform that aggregates 50+ rare and chronic disease patient communities into a single network offering news, forums, video content, and patient-reported data. It monetizes this audience by selling targeted Media & Advertising, RareSignal Research & Insights, Clinical Trial Recruitment, and Advocacy Partnerships solutions to pharmaceutical companies, biotechs, CROs, and patient advocacy organizations.

Product overview

BioNews operates as a unified platform consisting of a core network of 50+ rare and chronic disease community websites, supported by integrated service modules for Media & Advertising (targeted brand integration), RareSignal Research & Insights (patient survey and market research capabilities), Clinical Trial Support (patient recruitment), and Advocacy Partnerships. The company also produces branded content products including The Rare Journey immersive storytelling series and the Rare Trust in AI Index research publication. The platform serves both rare disease patients seeking information and pharmaceutical/clinical partners seeking to reach engaged, diagnosis-confirmed patient audiences.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rare Disease News & Community Network Network of 50+ rare and chronic disease news and community websites offering breaking research news, patient stories, forums, resource pages, advocacy partnerships, and social connections across conditions including ALS, Alzheimer's, Pompe, SMA, Myasthenia Gravis, and 45+ others. Built for rare disease patients, caregivers, and the pharma/biotech clients seeking to reach diagnosis-confirmed audiences.
  • Media & Advertising Targeted media solutions integrating brands within BioNews' trusted rare disease communities through eNewsletters, sponsored content hubs, brand pages, webinars, video content, conference coverage, and patient storytelling, reaching patients in clinical mindset moments. Sold to pharmaceutical and healthcare brand clients.
  • RareSignal (Research & Insights) Custom studies, rapid polls, panel development, focus groups, market research surveys, recruitment support, brand perception analysis, competitive analysis, patient input on trial design, and quality of life impact research delivered through BioNews' 50+ rare disease communities. Sold to pharma and biotech partners as a research service.
  • Clinical Trial Support Rare disease clinical trial recruitment through education, awareness building, and study design input. Connects patients with trials matching diagnosis, treatment history, and location for faster enrollment and higher retention. Sold to pharma, biotech, and CRO clients.
  • Advocacy Partnerships Collaborative programs with patient advocacy organizations to amplify advocacy efforts, expand access to reliable information, and support a more confident and engaged rare disease journey. Includes sponsored storytelling, patient collaborations, awareness initiatives, editorial and content partnerships, and HCP engagement programs.
  • The Rare Journey Immersive multimedia storytelling experience showcasing personal patient journey narratives, featuring Matt Lafleur's Friedreich's ataxia journey. Provides support and peer-to-peer connections for rare disease communities.
  • Rare Trust in AI Index Proprietary quarterly research index tracking how rare disease patients evaluate AI-generated health information against human-authored sources, providing insights on patient AI adoption and trust patterns across BioNews communities.

Quantifiable outcome

  • 3–5x industry-average engagement rate
  • +5 more outcomes

Companies that use BioNews

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

BioNews technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature5 records

BioNews partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor and core.

  • Digital Medicine Society (DiMe)minorStrategic or Co-development Partner · 23 June 2026DiMe (Digital Medicine Society) CEO Jennifer Goldsack participated as a panelist in the Bionews RWE Series webinar 'The Future of RWE' on June 23, 2026, discussing real-world evidence trends.
  • Parent Project Muscular DystrophyminorStrategic or Co-development Partner · 23 June 2026Megan Freed, Senior Director of Data & Health Technology Integration at Parent Project Muscular Dystrophy, participated as a panelist in the Bionews RWE Series webinar 'The Future of RWE'.
  • Foundation for the National Institutes of Health (FNIH)minorStrategic or Co-development Partner · 23 June 2026Tré LaRosa, Associate Project Manager at the Foundation for the National Institutes of Health, participated as a panelist in the Bionews RWE Series webinar.
  • ParexelminorStrategic or Co-development Partner · 23 June 2026Rachel Smith, Vice President of Rare and Genetic Disease at Parexel, participated as a panelist in the Bionews RWE Series webinar.
  • Decentralized Trials & Research Alliance (DTRA)minorStrategic or Co-development Partner · 23 June 2026Craig Lipset, Co-founder of DTRA, participated as a panelist in the Bionews RWE Series webinar discussing real-world evidence and decentralized trials.
  • CSL BehringminorStrategic or Co-development Partner · 23 June 2026Moshe Vardi, MD, Vice President of R&D and Global Head of Clinical Development at CSL Behring, participated as a panelist in the Bionews RWE Series webinar.
  • Journal of Participatory MedicineminorStrategic or Co-development Partner · 16 June 2026Amy Price, MS, MA, MS, DPhil, Editor in Chief of the Journal of Participatory Medicine, participated as a panelist in the Bionews RWE Series webinar 'The RWE Blindspot'.
  • Rona's Fun LabminorStrategic or Co-development Partner · 16 June 2026Lindsey Wahlstrom, Co-founder & Chief Momatologist at Rona's Fun Lab, participated as a panelist in the Bionews RWE Series webinar 'The RWE Blindspot'.
  • Mayo Clinic PaSAGE Study TeamcoreStrategic or Co-development Partner · 29 May 2024The Mayo Clinic PaSAGE (Patient-powered research for Advancement of Gene therapy Evidence) Study Team collaborates with Bionews to advance rare disease awareness and integrate patient voices into the therapeutic research process. PaSAGE is funded by the NIH. Bionews serves as a virtual forum where researchers, policymakers, and patients exchange ideas on gene editing. Marcella Debidda, President of Bionews Patient Insights & Clinical Solutions, participates in NIH-funded deliberative events alongside ethicists, gene therapists, philosophers, policymakers, and genetic counselors.
  • Patient Advocacy OrganizationscoreStrategic or Co-development PartnerBionews partners with patient advocacy organizations across its 50+ communities to amplify advocacy efforts, expand access to reliable information, and support patient journeys. Bionews provides platforms for advocacy groups to reach patients and contribute resources, forums, and support to communities.
  • Top 20 Pharmaceutical Companies (Client Partners)coreGTM or Marketing PartnerBionews counts the top 20 pharmaceutical companies among its client base, providing media, research, and clinical trial recruitment solutions. These partnerships are commercial client relationships where pharma companies pay for access to Bionews' patient communities.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

BioNews competitors and assessment

Company assessment

Emerging players

  • Clara Health: Clinical trial access platform focused on improving patient recruitment and trial awareness. Comparable enterprise motion to pharma and CROs though with less emphasis on condition-specific community depth.
  • SmartPatients: Online patient community with an embedded clinical trial matching tool and pharma insights offerings. Niche overlap with BioNews on community-driven trial recruitment and patient intelligence.

Direct peers

  • BBK Worldwide: Long-standing patient recruitment and engagement agency for clinical trials across therapeutic areas. Comparable enterprise sales motion to pharma and CROs for trial enrollment acceleration.
  • WEGO Health: Patient influencer network connecting pharma and biotech with patient leaders across chronic and rare conditions. Closely comparable to BioNews' patient-community and lived-experience model for pharma engagement and insights.
  • Rare Patient Voice: Specializes in connecting rare disease patients and caregivers to market research and clinical trial opportunities. Directly competes with BioNews' RareSignal research and clinical trial recruitment offerings in the rare disease vertical.
  • Antidote: Clinical trial matching platform that recruits patients from partner communities for sponsors and CROs. Comparable to BioNews' clinical trial recruitment revenue stream and pharma partner motion.
  • Inspire: Operates condition-specific patient communities and partners with life sciences companies for research, clinical trial recruitment, and real-world evidence. Directly comparable as a community-platform-to-pharma intermediary.

Broad incumbents

  • Healthline: Large general-consumer health media property owned by RVO Health, monetized via pharma advertising and content partnerships. Competes for the same pharma media budgets but without BioNews' diagnosis-confirmed, rare-disease depth.
  • WebMD: Broad health information platform with significant pharma media and sponsored content revenue. A large incumbent that competes for pharma media dollars but lacks BioNews' rare disease community authenticity.

Others

  • EveryLife Foundation for Rare Diseases: Rare disease policy and advocacy organization that convenes patient communities and engages with pharma/biotech. Adjacent ecosystem participant rather than a commercial competitor, but overlaps on patient-voice and pharma partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BioNews social profiles

Digital presence

BioNews financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioNews leadership team

Management profile

Number of profiles

Profiles9 records

BioNews funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioNews M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioNews

What does BioNews do?

BioNews operates a digital health media platform that aggregates 50+ rare and chronic disease patient communities into a single network offering news, forums, video content, and patient-reported data. It monetizes this audience by selling targeted Media & Advertising, RareSignal Research & Insights, Clinical Trial Recruitment, and Advocacy Partnerships solutions to pharmaceutical companies, biotechs, CROs, and patient advocacy organizations.

Is BioNews a public or private company?

BioNews is a private company. It is classified as unknown and is currently operating.

When was BioNews founded?

BioNews was founded in 2013. It employs 101 to 250 people.

Where is BioNews based?

BioNews is headquartered in Pensacola, United States, in the North America region.

How does BioNews make money?

Four revenue lines are on record. Media & Advertising is the primary driver. The others are clinical Trial Recruitment Services, market Research & Insights (RareSignal) and advocacy Partnerships & Sponsored Content.

Who are BioNews's main competitors?

Emerging players on record are Clara Health and SmartPatients. Direct peers are BBK Worldwide, WEGO Health, Rare Patient Voice, Antidote and Inspire. Broad incumbents are Healthline and WebMD. EveryLife Foundation for Rare Diseases is listed as an others.

Does BioNews have an API?

No public API is recorded for BioNews.

What industry is BioNews in?

BioNews's product category is Rare Disease Patient Media & Insights. Its primary akta.pro industry code is MPACAJAL, Health, Wellness & Patient Communities, with a secondary code of HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D). Its NAICS code is 51621 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals